623582-53-6

Usage

Uses

Used in Organic Synthesis:
Tert-butyl (3R)-3-[(benzyloxy)carbonyl]aMino-4-(hydroxyMethyl) is used as a protecting group for amines, ensuring that they remain stable and unreacted during the synthesis of complex molecules. This is particularly important in the creation of intricate organic structures where unwanted reactions can lead to the formation of undesired byproducts.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Tert-butyl (3R)-3-[(benzyloxy)carbonyl]aMino-4-(hydroxyMethyl) is considered a potential building block for the development of new pharmaceutical compounds. Its unique structure may contribute to the creation of novel drugs with specific therapeutic properties. Further research and testing are required to fully understand its potential applications and to optimize its use in drug design.

Upstream product

• 623582-43-4 1-(2-hydroxy-1-phenyl-ethyl)-tetrahydro-pyrrolo[3,4-c]isoxazole-5-carboxylic acid tert-butyl ester 
• 251948-88-6 N-allyl-N-(tert-butyloxycarbonyl)-glycinal 
• 31954-27-5 N-(tert-butoxycarbonyl)glycine methyl ester 
• 116613-80-0 N-allyl-N-(tert-butoxycarbonyl)glycine methyl ester 
• 501-53-1 benzyl chloroformate 
• 1184918-34-0 (3R,4R)-3-amino-4-hydroxymethyl-N-t-butoxycarbonylpyrrolidine 

Downstream Products

• 1207852-57-0 C₁₉H₂₈N₂O₇S 
• 369623-85-8 (3R,4R)-4-Amino-pyrrolidine-1,3-dicarboxylic acid 1-tert-butyl ester 
• 623582-51-4 (3R,4R)-4-(((benzyloxy)carbonyl) amino)-1-(tert-butoxycarbonyl)pyrrolidine-3-carboxylic acid 

Relevant academic research and scientific papers

Synthesis of Cyclic and Acyclic β-Amino Acids via Chelation-Controlled 1,3-Dipolar Cycloaddition

Isoxazolidines have been synthesized in diastereomeric excess up to 94% via a MgBr2-induced chelation-controlled 1,3-dipolar cycloaddition reaction with N-hydroxyphenylglycinol as a chiral auxiliary. The diastereomerically pure isoxazolidines were further transformed into cyclic and acyclic β-amino acid derivatives.

Novel α- and β-amino acid inhibitors of influenza virus neuraminidase

In an effort to discover novel, noncarbohydrate inhibitors of influenza virus neuraminidase we hypothesized that compounds which contain positively charged amino groups in an appropriate position to interact with the Asp 152 or Tyr 406 side chains might be bound tightly by the enzyme. Testing of 300 α- and β-amino acids led to the discovery of two novel neuraminidase inhibitors, a phenylglycine and a pyrrolidine, which exhibited Ki values in the 50 μM range versus influenza virus A/N2/Tokyo/3/67 neuraminidase but which exhibited weaker activity against influenza virus B/Memphis/3/89 neuraminidase. Limited optimization of the pyrrolidine series resulted in a compound which was about 24-fold more potent than 2-deoxy-2,3-dehydro-N-acetylneuraminic acid in an anti-influenza cell culture assay using A/N2/Victoria/3/75 virus. X-ray structural studies of A/N9 neuraminidase-inhibitor complexes revealed that both classes of inhibitors induced the Glu 278 side chain to undergo a small conformational change, but these compounds did not show time-dependent inhibition. Crystallography also established that the α-amino group of the phenylglycine formed hydrogen bonds to the Asp 152 carboxylate as expected. Likewise, the β-amino group of the pyrrolidine forms an interaction with the Tyr 406 hydroxyl group and represents the first compound known to make an interaction with this absolutely conserved residue. Phenylglycine and pyrrolidine analogs in which the α- or β-amino groups were replaced with hydroxyl groups were 365- and 2,600-fold weaker inhibitors, respectively. These results underscore the importance of the amino group interactions with the Asp 152 and Tyr 406 side chains and have implications for anti-influenza drug design.